logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals gets green light from data and safety board to continue Phase 2b-3 study

Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has heard from the external Data and Safety Monitoring Board who has once again unanimously approved the continuation of the Company’s multinational Phase 2b/3 human study of Ifenprodil for the treatment of COVID-19.

Moreau talks about moving forward also about why he thinks this says about their drug compared to others.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.235 CAD

CSE:AGN
Market: CSE
Market Cap: $32.51 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Algernon Pharmaceuticals sees positive trending interim data from Phase 2b/3...

Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive with news the company has received interim data from the Phase 2b part of their Phase 2b/3 clinical study of Ifenprodil for COVID-19. Moreau telling Proactive what the data showed...

on 15/12/20

2 min read